Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STI571 Extension in Ph+ Leukemias
NCT00171249Phase 2Completed
- Sponsor
- Novartis
- Start
- Aug 1999
- Primary completion
- Sep 2013
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label trial of imatinib in chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) (7 arms), sponsored by Novartis. Primary endpoint: Percentage of Participants With Hematologic Response in Accelerated Phase Chronic Myeloid/Myelogenous Leukemia up to 3 years. Started Aug 1999; status: completed.
02
Drugs
03
Conditions
chronic myeloid leukemia (CML)acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00171249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00171249.